Study 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology Study 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology Commentaries: Antithrombotic prophylaxis […]

The post Two new studies show no benefit of Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19. appeared first on Links Medicus.